Firefly Neuroscience, an artificial intelligence firm dedicated to enhancing brain health outcomes, announced on Tuesday a significant breakthrough in research related to estimating the biological age of the brain. This advancement is achieved through its FDA-approved BNA technology platform.
The BNA system utilizes data from Resting EEG and Cognitive EEG to evaluate the brain age of patients. This innovative method can identify a substantial gap between an individual's brain age and chronological age, which may be a critical risk factor for developing dementia.
According to the company, employing EEG to assess brain age offers a proactive and scalable approach for the early detection of Alzheimer's disease.
As of September 30, 2024, Firefly Neuroscience reported a cash reserve of $1.2 million.
Presently, the company's stock, AIFF, is trading at $4.58, marking a 140% increase.
